|
US5858980A
(en)
*
|
1990-03-30 |
1999-01-12 |
Autoimmune, Inc. |
Peptide fragments of myelin basic protein
|
|
US7090982B2
(en)
|
1991-10-22 |
2006-08-15 |
The Governors Of The University Of Alberta |
Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
|
|
US6252040B1
(en)
|
1991-10-22 |
2001-06-26 |
The Governors Of The University Of Alberta |
Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
|
|
US5800808A
(en)
|
1994-05-24 |
1998-09-01 |
Veda Research And Development Co., Ltd. |
Copolymer-1 improvements in compositions of copolymers
|
|
US5858964A
(en)
*
|
1995-04-14 |
1999-01-12 |
Yeda Research And Development Co. Ltd. |
Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
|
|
IL119989A0
(en)
*
|
1997-01-10 |
1997-04-15 |
Yeda Res & Dev |
Pharmaceutical compositions for oral treatment of multiple sclerosis
|
|
HUP0100891A2
(hu)
*
|
1998-02-13 |
2001-06-28 |
Autoimmune, Inc. |
A COP-1 és Th2 fokozó citokinek gyógyászati alkalmazása
|
|
WO2000005249A2
(en)
|
1998-07-23 |
2000-02-03 |
The President And Fellows Of Harvard College |
Synthetic peptides and methods of use for autoimmune disease therapies
|
|
ES2527760T3
(es)
*
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
IL141021A0
(en)
|
1998-07-23 |
2002-02-10 |
Yeda Res & Dev |
Treatment of autoimmune conditions with copolymer 1 and related copolymers
|
|
US6514938B1
(en)
|
1998-09-25 |
2003-02-04 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
ES2369642T3
(es)
|
1998-09-25 |
2011-12-02 |
Yeda Research And Development Co., Ltd. |
Polipéptidos relacionados con el copolímero 1 para su uso como marcadores de pesos moleculares y para uso terapéutico.
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
WO2000020010A1
(en)
*
|
1998-10-02 |
2000-04-13 |
Yeda Research And Development Co., Ltd. |
Alternate day administration of copolymer 1 for treating autoimmune diseases
|
|
US7083777B1
(en)
|
1999-04-02 |
2006-08-01 |
The Brigham And Women's Hospital, Inc. |
Immunomodulating polymers
|
|
ATE302020T1
(de)
*
|
2000-01-20 |
2005-09-15 |
Yeda Res & Dev |
Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
|
|
ATE329608T1
(de)
*
|
2000-02-18 |
2006-07-15 |
Yeda Res & Dev |
Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
|
|
ZA200206457B
(en)
*
|
2000-02-18 |
2003-08-13 |
Yeda Res & Dev |
Oral, nasal and pulmonary dosage formulations of copolymer 1.
|
|
US20020077278A1
(en)
*
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
CA2411536A1
(en)
*
|
2000-06-05 |
2001-12-13 |
V. Wee Yong |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
DK1294390T3
(da)
*
|
2000-06-07 |
2006-04-03 |
Yeda Res & Dev |
Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celelr behandlet dermed til neurobeskyttelse mod glutamattoksicitet
|
|
WO2002076503A1
(en)
*
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
WO2001097785A2
(en)
*
|
2000-06-20 |
2001-12-27 |
Caprion Pharmaceuticals Inc. |
Basic copolymers for the treatment of prion-related-disease
|
|
IL137460A0
(en)
*
|
2000-07-24 |
2001-07-24 |
Yeda Res & Dev |
Identifying antigen clusters for monitoring a global state of an immune system
|
|
US20040037828A1
(en)
|
2002-07-09 |
2004-02-26 |
Bar-Ilan University |
Methods and pharmaceutical compositions for healing wounds
|
|
SV2003000753A
(es)
|
2000-12-05 |
2003-06-16 |
Brigham & Womens Hospital |
Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
|
|
GB2369896A
(en)
|
2000-12-06 |
2002-06-12 |
Marconi Comm Ltd |
Tunable optical filter actuator
|
|
KR100442122B1
(ko)
*
|
2001-07-31 |
2004-07-30 |
한국전기연구원 |
영구 자석을 이용한 브러시리스 발전기
|
|
KR100657048B1
(ko)
*
|
2001-12-04 |
2006-12-12 |
테바 파마슈티컬 인더스트리즈 리미티드 |
글라티라머 아세테이트의 효능 측정 방법
|
|
CA2469092C
(en)
*
|
2001-12-06 |
2013-02-19 |
Yeda Research And Development Co. Ltd |
Copolymer 1 vaccine and methods for treatment of amyotrophic lateral sclerosis (als)
|
|
US20060057107A1
(en)
*
|
2001-12-21 |
2006-03-16 |
Shaked Ze Ev |
Combination treatment for multiple sclerosis
|
|
CA2411786C
(en)
|
2002-11-13 |
2009-01-27 |
Brantford Chemicals Inc. |
A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
|
|
JP5291878B2
(ja)
|
2003-01-07 |
2013-09-18 |
イエダ リサーチ アンド デベロップメント カンパニー リミテッド |
治療的免疫のためのコポリマー１を含む点眼ワクチン
|
|
AU2004206120B2
(en)
*
|
2003-01-21 |
2009-09-24 |
Yeda Research And Development Co. Ltd. |
COP 1 for treatment of inflammatory bowel diseases
|
|
EP1603530A1
(en)
*
|
2003-03-04 |
2005-12-14 |
Teva Pharmaceutical Industries Limited |
Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
|
|
AU2004227852B2
(en)
|
2003-03-31 |
2010-01-14 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic immunomodulators for the treatment of asthma and allergy
|
|
EA200600877A1
(ru)
*
|
2003-10-31 |
2006-12-29 |
Тева Фармасьютикал Индастриз, Лтд. |
Наночастицы для доставки лекарств
|
|
CA2546077C
(en)
|
2003-11-12 |
2016-07-05 |
Yeda Research And Development Co. Ltd. |
Vaccine and method for treatment of neurodegenerative diseases
|
|
PT1701730E
(pt)
|
2003-12-09 |
2013-11-27 |
Yeda Res & Dev |
Método e vacina compreendendo copolímero 1 para tratamento de distúrbios psiquiátricos
|
|
EP1725099A4
(en)
*
|
2004-02-02 |
2009-08-19 |
Mixture Sciences Inc |
PEPTIDE MIXTURES WITH IMMUNOMODULATIVE ACTIVITY
|
|
KR20060125916A
(ko)
*
|
2004-03-01 |
2006-12-06 |
펩팀문, 인코포레이티드 |
자가면역 질병을 치료하기 위한 방법 및 조성물
|
|
EP1778286A4
(en)
*
|
2004-03-03 |
2009-04-08 |
Teva Pharma |
COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
|
|
US20050260770A1
(en)
*
|
2004-04-01 |
2005-11-24 |
Cohen Irun R |
Antigen array and diagnostic uses thereof
|
|
NZ551236A
(en)
|
2004-05-07 |
2010-11-26 |
Peptimmune Inc |
Methods of treating disease with random copolymers
|
|
US20060194725A1
(en)
*
|
2004-05-07 |
2006-08-31 |
James Rasmussen |
Methods of treating disease with random copolymers
|
|
US7655221B2
(en)
*
|
2004-05-07 |
2010-02-02 |
Peptimmune, Inc. |
Methods of treating disease with random copolymers
|
|
EP2332570A1
(en)
|
2004-06-25 |
2011-06-15 |
ID Biomedical Corporation of Quebec |
Compositions and methods for treating neurological disorders
|
|
HUE028833T2
(en)
*
|
2004-09-09 |
2017-01-30 |
Yeda Res & Dev |
Polypeptide mixtures, compositions containing them, process for their preparation, and applications
|
|
ES2451006T3
(es)
*
|
2004-09-09 |
2014-03-26 |
Teva Pharmaceutical Industries Ltd. |
Procedimiento para la preparación de mezclas de acetato de trifluoroacetilglatirámero usando ácido bromhídrico purificado
|
|
US8324641B2
(en)
*
|
2007-06-29 |
2012-12-04 |
Ledengin, Inc. |
Matrix material including an embedded dispersion of beads for a light-emitting device
|
|
DE602005016292D1
(de)
*
|
2004-10-29 |
2009-10-08 |
Sandoz Ag |
Verfahren zur herstellung von glatiramer
|
|
WO2006057003A2
(en)
*
|
2004-11-29 |
2006-06-01 |
Yeda Research And Development Co. Ltd. |
Induction of neurogenesis and stem cell therapy in combination with copolymer 1
|
|
UA93669C2
(ru)
*
|
2005-02-02 |
2011-03-10 |
Тева Фармасьютикл Индастриз, Лтд. |
Способ приготовления полипептидной смеси c использованием гидрогенолиза
|
|
PL1848415T3
(pl)
*
|
2005-02-17 |
2013-10-31 |
Teva Pharma |
Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
|
|
US20100167983A1
(en)
*
|
2007-10-22 |
2010-07-01 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
|
|
US20060240463A1
(en)
*
|
2005-04-25 |
2006-10-26 |
Rappaport Family Institute For Research In The Medical Sciences |
Markers associated with the therapeutic efficacy of glatiramer acetate
|
|
WO2007081975A2
(en)
*
|
2006-01-11 |
2007-07-19 |
Teva Pharmaceutical Industries, Ltd. |
Method of treating multiple sclerosis
|
|
US8206726B2
(en)
|
2006-02-06 |
2012-06-26 |
The Brigham And Women's Hospital, Inc. |
Zwitterionic polysaccharides for promotion of immune system maturation and health
|
|
JP2009536157A
(ja)
|
2006-04-13 |
2009-10-08 |
ペプチミューン，インコーポレイテッド |
エピトープ透過性の指向された拡張を介した指向性配列ポリマー組成物の設計方法および合成方法
|
|
CA2650653C
(en)
*
|
2006-04-28 |
2016-03-29 |
Momenta Pharmaceuticals, Inc. |
Methods of evaluating glatiramer acetate
|
|
KR100831796B1
(ko)
*
|
2006-05-29 |
2008-05-28 |
엘지전자 주식회사 |
타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
|
|
US9089509B2
(en)
|
2006-06-28 |
2015-07-28 |
Yeda Research And Development Co., Ltd. |
Method of treatment of age-related macular degeneration
|
|
EP2046817B1
(en)
*
|
2006-07-05 |
2009-12-16 |
Momenta Pharmaceuticals, Inc. |
Improved process for the preparation of copolymer-1
|
|
ES2477232T5
(es)
|
2007-06-21 |
2017-11-23 |
Momenta Pharmaceuticals, Inc. |
Análisis de copolímeros
|
|
US20090029766A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Lutnick Howard W |
Amusement gaming access and authorization point
|
|
WO2009016643A1
(en)
*
|
2007-07-31 |
2009-02-05 |
Natco Pharma Limited |
Process for the preparation glatiramer acetate (copolymer-1)
|
|
AP3467A
(en)
|
2007-10-16 |
2015-11-30 |
Peptimmune Inc |
Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
|
|
WO2009062132A2
(en)
|
2007-11-09 |
2009-05-14 |
California Institute Of Technology |
Immunomodulating compounds and related compositions and methods
|
|
WO2009070298A1
(en)
*
|
2007-11-28 |
2009-06-04 |
Teva Pharmaceutical Industries, Ltd. |
Method of delaying the onset of clinically definite multiple sclerosis
|
|
EP2277050B2
(en)
|
2008-04-16 |
2022-09-28 |
Momenta Pharmaceuticals, Inc. |
Analysis of amino acid copolymer compositions
|
|
HUE025042T2
(en)
*
|
2008-08-07 |
2016-07-28 |
Sigma Aldrich Co Llc |
High-yield production of low molecular weight polylysine and poliornitine
|
|
WO2010017292A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Scinopharm Taiwan, Ltd. |
Synthesis of glatiramer acetate
|
|
AR074881A1
(es)
|
2008-12-24 |
2011-02-16 |
Synthon Bv |
Un proceso para purificar una mezcla de polimeros
|
|
RU2011144566A
(ru)
|
2009-04-03 |
2013-05-10 |
Момента Фармасьютикалз, Инк. |
Контроль сополимерных композиций
|
|
AU2009347384B2
(en)
|
2009-06-04 |
2014-10-23 |
Council Of Scientific & Industrial Research |
A process for the preparation of copolymer - 1 (Cop-I), composed of L-alanine, L-lysine, L-glutamic acid and L-tyrosine-drug for the treatment of multiple sclerosis
|
|
US8920373B2
(en)
|
2009-07-15 |
2014-12-30 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
CA2697570C
(en)
*
|
2009-07-15 |
2011-11-01 |
Teva Pharmaceutical Industries, Ltd. |
Reduced volume formulation of glatiramer acetate and methods of administration
|
|
US8691790B2
(en)
*
|
2009-07-27 |
2014-04-08 |
James Layne Boucher |
Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
|
|
DE202010018377U1
(de)
|
2009-08-20 |
2016-02-25 |
Yeda Research And Development Co., Ltd. |
Niedrigfrequente therapie mit glatirameracetat
|
|
CA2784394C
(en)
|
2010-01-04 |
2016-12-13 |
Mapi Pharma Limited |
Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof
|
|
US8377885B2
(en)
|
2010-01-04 |
2013-02-19 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
EP2523668A1
(en)
|
2010-01-13 |
2012-11-21 |
Ramot at Tel-Aviv University Ltd |
Treatment of multiple sclerosis
|
|
US8759302B2
(en)
*
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
US20110251156A1
(en)
|
2010-04-07 |
2011-10-13 |
Yue Shen |
Vehicle for delivering a compound to a mucous membrane and related compositions, methods and systems
|
|
US20130281663A1
(en)
*
|
2010-04-27 |
2013-10-24 |
Dr. Reddy's Laboratories, Inc. |
Preparation of polypeptides and salts thereof
|
|
CA2800174A1
(en)
|
2010-05-20 |
2011-11-24 |
June L. Round |
Antigen specific tregs and related compositions, methods and systems
|
|
CA2806997A1
(en)
*
|
2010-07-29 |
2012-02-02 |
Dr. Reddy's Laboratories Ltd. |
Glatiramer acetate molecular weight markers
|
|
US8709433B2
(en)
|
2010-10-11 |
2014-04-29 |
Teva Pharmaceutical Industries Ltd. |
Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
|
|
US9029507B2
(en)
|
2011-02-14 |
2015-05-12 |
Usv Limited |
Copolymer-1, process for preparation and analytical methods thereof
|
|
EP2699317B1
(en)
*
|
2011-04-21 |
2016-08-10 |
Mapi Pharma Limited |
Random pentapolymer for treatment of autoimmune diseases
|
|
WO2012150495A1
(en)
|
2011-05-05 |
2012-11-08 |
National Institute Of Immunology |
Synthetic peptides and random copolymers for the treatment of autoimmune disorders
|
|
WO2013009885A2
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Evaluation of copolymer diethylamide
|
|
WO2013009864A1
(en)
|
2011-07-11 |
2013-01-17 |
Momenta Pharmaceuticals, Inc. |
Structure assessment of heterogeneous polypeptide mixtures
|
|
EP2731617A4
(en)
|
2011-07-12 |
2015-07-01 |
Brigham & Womens Hospital |
LIPID-CONTAINING PSA COMPOSITIONS, METHODS OF ISOLATION AND METHODS OF USING SAME
|
|
US8575198B1
(en)
|
2011-09-07 |
2013-11-05 |
Momenta Pharmaceuticals, Inc. |
In-process control for the manufacture of glatiramer acetate
|
|
JP2014530819A
(ja)
|
2011-10-10 |
2014-11-20 |
テバ ファーマシューティカル インダストリーズ リミティド |
酢酸グラチラマーに対する臨床的応答性を予測するために有用な一塩基多形
|
|
EP2642290A1
(en)
|
2012-03-19 |
2013-09-25 |
Synthon BV |
Glatiramer acetate human monocytic cell line-based potency assay
|
|
WO2013139728A1
(en)
|
2012-03-19 |
2013-09-26 |
Synthon Bv |
Glatiramer acetate human monocyte cell-based potency assay
|
|
US20140045740A1
(en)
*
|
2012-08-13 |
2014-02-13 |
Momenta Pharmaceuticals, Inc. |
Analysis of glatiramer acetate
|
|
MX2015004563A
(es)
|
2012-10-10 |
2015-07-14 |
Teva Pharma |
Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
|
|
WO2014060942A2
(en)
*
|
2012-10-20 |
2014-04-24 |
Mahesh Kandula |
Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases
|
|
WO2014128079A1
(en)
|
2013-02-19 |
2014-08-28 |
Synthon B.V. |
Glatiramer acetate multidose formulation
|
|
SI2774639T1
(sl)
|
2013-03-08 |
2015-05-29 |
Teva Pharmaceutical Industries, Ltd. |
Injektorska naprava za brizgo, primerna za večkratno uporabo
|
|
EP2774640B1
(en)
|
2013-03-08 |
2014-12-31 |
Teva Pharmaceutical Industries, Ltd. |
Re-useable injector device for syringe
|
|
US10344330B2
(en)
|
2013-03-14 |
2019-07-09 |
Mylan Inc. |
Glatiramer acetate response biomarker mRNA potency assay
|
|
WO2014173463A1
(en)
|
2013-04-26 |
2014-10-30 |
Synthon Bv |
Glatiramer acetate human monocytic cell line-based potency assay
|
|
EP2994161B1
(en)
|
2013-05-10 |
2020-10-28 |
California Institute of Technology |
Probiotic prevention and treatment of colon cancer
|
|
CN103265624B
(zh)
*
|
2013-05-27 |
2015-04-22 |
成都圣诺生物制药有限公司 |
格拉替雷的制备方法
|
|
CN104371012A
(zh)
*
|
2013-08-12 |
2015-02-25 |
深圳翰宇药业股份有限公司 |
一种合成醋酸格拉替雷的方法
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
AU2014340010B2
(en)
|
2013-10-24 |
2021-05-27 |
Mylan Inc. |
Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
|
|
US10545144B2
(en)
|
2013-12-31 |
2020-01-28 |
Yeda Research And Development Co., Ltd. |
Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
|
|
KR20200029627A
(ko)
|
2014-03-12 |
2020-03-18 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
|
|
CN104844697B
(zh)
|
2014-09-26 |
2018-10-23 |
深圳翰宇药业股份有限公司 |
醋酸格拉替雷的制备方法
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
|
EP3265814B1
(en)
|
2015-03-01 |
2020-11-18 |
Immunarray Ltd. |
Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
|
|
US11331335B2
(en)
|
2015-06-10 |
2022-05-17 |
California Institute Of Technology |
Sepsis treatment and related compositions methods and systems
|
|
JP6918365B2
(ja)
|
2015-08-19 |
2021-08-11 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
脂質化ｐｓａ組成物および方法
|
|
ES2744179T3
(es)
|
2015-09-24 |
2020-02-24 |
Chemi Spa |
Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas
|
|
ES2707500T3
(es)
|
2015-11-23 |
2019-04-03 |
Chemi Spa |
Análisis mediante RP-HPLC de mezclas de polipéptidos complejos
|
|
CN107522774B
(zh)
*
|
2016-06-22 |
2021-07-02 |
深圳翰宇药业股份有限公司 |
一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
|
|
EP3478300B1
(en)
|
2016-06-30 |
2022-08-24 |
Stem Cell Medicine Ltd. |
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
|
|
US11491181B2
(en)
|
2016-07-15 |
2022-11-08 |
President And Fellows Of Harvard College |
Glycolipid compositions and methods of use
|
|
EP3503907B1
(en)
|
2016-08-28 |
2024-03-13 |
Mapi Pharma Ltd. |
Process for preparing microparticles containing glatiramer acetate
|
|
US12097292B2
(en)
|
2016-08-28 |
2024-09-24 |
Mapi Pharma Ltd. |
Process for preparing microparticles containing glatiramer acetate
|
|
CN109982712A
(zh)
|
2016-08-31 |
2019-07-05 |
Mapi医药公司 |
包含醋酸格拉替雷的储库系统
|
|
WO2018178973A1
(en)
|
2017-03-26 |
2018-10-04 |
Mapi Pharma Ltd. |
Glatiramer depot systems for treating progressive forms of multiple sclerosis
|
|
CN110709091A
(zh)
|
2017-05-15 |
2020-01-17 |
干细胞医药有限公司 |
使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症
|
|
WO2018211498A1
(en)
|
2017-05-15 |
2018-11-22 |
Stem Cell Medicine Ltd. |
Treatment of multiple sclerosis with adipose-derived stem cells
|
|
WO2019175869A1
(en)
|
2018-03-12 |
2019-09-19 |
Yeda Research And Development Co. Ltd |
Treatment of a heart disease
|